- Home
- WSHP vs MCRB Comparison
WSHP vs MCRB Comparison
Compare WSHP & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WSHP | MCRB |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | British Virgin Islands | United States |
| Employees | 20 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.7M | 71.0M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | WSHP | MCRB |
|---|---|---|
| Price | $5.50 | $6.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | 48.5K | ★ 69.8K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.95 | $5.31 |
| 52 Week High | $250.00 | $29.98 |
Technical Indicators
Market Signals| Indicator | WSHP | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 40.17 | 44.24 |
| Support Level | $5.05 | N/A |
| Resistance Level | $7.50 | $9.53 |
| Average True Range (ATR) | 0.54 | 0.77 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 19.36 | 46.72 |
Price Performance
Historical ComparisonAbout WSHP WeShop Holdings Limited Class A Ordinary Shares
WeShop Holdings Ltd is a community owned social commerce platform offering shoppers shares in the company every time customers make a purchase, recommend a product or refer a new member. WeShop earns revenues from advertising on their platform and commissions on the sales through the platform.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.